• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

    9.335 -0.045 (-0.48%)
    Streaming Delayed Price Updated: 10:37 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Design Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Design Therapeutics to Participate in Upcoming Investor Conferences
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Appoints Justin Gover to Board of Directors
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
    Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
    From Bright Peak Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
    From Design Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.